Galectin Therapeutics (GALT) Competitors $0.84 -0.05 (-5.56%) (As of 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GALT vs. DMAC, MOLN, PRQR, LFVN, SOPH, NLTX, INBX, ACRS, CRDF, and LXEOShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include DiaMedica Therapeutics (DMAC), Molecular Partners (MOLN), ProQR Therapeutics (PRQR), LifeVantage (LFVN), SOPHiA GENETICS (SOPH), Neoleukin Therapeutics (NLTX), Inhibrx (INBX), Aclaris Therapeutics (ACRS), Cardiff Oncology (CRDF), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. DiaMedica Therapeutics Molecular Partners ProQR Therapeutics LifeVantage SOPHiA GENETICS Neoleukin Therapeutics Inhibrx Aclaris Therapeutics Cardiff Oncology Lexeo Therapeutics DiaMedica Therapeutics (NASDAQ:DMAC) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends. Which has stronger earnings and valuation, DMAC or GALT? DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-9.39Galectin TherapeuticsN/AN/A-$41.07M-$0.73-1.15 Which has more volatility and risk, DMAC or GALT? DiaMedica Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Is DMAC or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% Galectin Therapeutics N/A N/A -163.15% Do analysts prefer DMAC or GALT? DiaMedica Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 33.08%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 1,208.59%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor DMAC or GALT? In the previous week, Galectin Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 3 mentions for DiaMedica Therapeutics. Galectin Therapeutics' average media sentiment score of 0.08 beat DiaMedica Therapeutics' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galectin Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in DMAC or GALT? 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in DMAC or GALT? Galectin Therapeutics received 254 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. However, 62.84% of users gave DiaMedica Therapeutics an outperform vote while only 59.32% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% Galectin TherapeuticsOutperform Votes34759.32% Underperform Votes23840.68% SummaryGalectin Therapeutics beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.76M$6.71B$5.23B$9.27BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-1.1510.5887.5817.29Price / SalesN/A195.781,167.56119.73Price / CashN/A57.1543.2337.83Price / Book-0.835.164.834.93Net Income-$41.07M$151.58M$120.46M$225.34M7 Day Performance-60.35%-0.64%-0.26%1.13%1 Month Performance-69.76%-3.02%15.99%2.76%1 Year Performance-52.51%8.81%30.22%16.90% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.9783 of 5 stars$0.84-5.6%$11.00+1,208.6%-49.7%$52.76MN/A-1.159News CoverageHigh Trading VolumeDMACDiaMedica Therapeutics1.7878 of 5 stars$5.22-18.6%$7.00+34.1%+88.8%$223.21MN/A-9.3220Gap DownHigh Trading VolumeMOLNMolecular Partners0.3657 of 5 stars$5.44+4.2%N/A+19.0%$219.58M$6.00M-2.53180News CoverageGap UpPRQRProQR Therapeutics1.7088 of 5 stars$2.64+0.4%$7.60+187.9%+40.5%$215.64M$17.88M-8.25180LFVNLifeVantage4.5627 of 5 stars$17.14-1.3%$26.00+51.7%+166.3%$214.68M$196.01M53.56260SOPHSOPHiA GENETICS2.5059 of 5 stars$3.28+0.6%$7.40+125.6%-27.3%$214.43M$64.49M-3.01520NLTXNeoleukin TherapeuticsN/A$22.64+2.6%N/A+47.0%$212.77MN/A-7.2890High Trading VolumeINBXInhibrx1.4248 of 5 stars$14.58-0.1%N/A-53.7%$211.06M$1.57M0.00166Gap DownACRSAclaris Therapeutics3.7973 of 5 stars$2.94+8.1%$11.00+274.1%+170.1%$210.01M$27.08M-5.6586Analyst UpgradeNews CoverageGap UpCRDFCardiff Oncology1.4699 of 5 stars$4.06-4.7%$10.33+154.5%+176.9%$207.60M$688,000.00-4.3220LXEOLexeo Therapeutics2.8366 of 5 stars$6.27-0.2%$23.80+279.6%-60.1%$207.32M$650,000.00-1.9858 Related Companies and Tools Related Companies DMAC Alternatives MOLN Alternatives PRQR Alternatives LFVN Alternatives SOPH Alternatives NLTX Alternatives INBX Alternatives ACRS Alternatives CRDF Alternatives LXEO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GALT) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
